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H ypertension is one of the major risk factors for ischemic stroke, and the occurrence of acute ischemic stroke (AIS) commonly enhances high blood pressure (BP) in hypertensive patients. 1, 2 However, there is no available definitive evidence indicating the benefit of acute BP lowering with antihypertensive drugs in the clinical outcome of AIS. Previous reports are conflicting as to whether antihypertensive therapy at the acute phase is beneficial or detrimental for the outcome of AIS. [2] [3] [4] The potential benefit of antihypertensive therapy seems to be dependent on the extent, period, or method of BP lowering. 3, 4 Bilateral renal denervation (RD) is postulated to be a novel promising option of antihypertensive therapy in some hypertensive patients, such as those with resistant hypertension. 5, 6 Apart from the effects on BP, RD is suggested to exert beneficial cardiovascular and brain effects. 6, 7 We have previously reported that RD pretreatment significantly slows primary stroke onset in hypertensive rats, through the attenuation of oxidative stress and brain injury, 7 thereby highlighting RD as a novel preventive strategy for the onset of stroke. However, it remains to be determined whether RD posttreatment can provide neurovascular protection in AIS.
The main purpose of this preclinical study was to demonstrate our hypothesis that RD posttreatment can improve the outcome of a rat model of AIS, which was prepared by transient middle cerebral artery occlusion (MCAO) of hypertensive rats.
Methods
Spontaneously hypertensive stroke-prone rats (SHRSPs) were divided into (1) a control group and (2) 90-minute MCAO group. The rats in the latter group were further separated into (1) RD and (2) sham-operated groups. RD was performed at 30 minutes after the start of MCAO. Next, Wistar Kyoto rats were used to evaluate the effect of RD posttreatment in normotensive ischemic stroke. In addition, other SHRSPs were rendered MCAO at 7 days after RD or sham Background and Purpose-Renal denervation (RD) may protect against cardiovascular diseases regardless of blood pressure (BP)-lowering effect. We hypothesized that RD can improve the outcome of acute ischemic stroke (AIS) in hypertensive rats. Methods-An AIS model of spontaneously hypertensive stroke-prone rats (SHRSPs) was prepared by 90-minute middle cerebral artery occlusion followed by reperfusion. At 30 minutes poststroke, the SHRSPs were subjected to (1) sham operation or (2) RD to determine the beneficial effects of RD posttreatment. In addition, we evaluated the neuroprotective effects of RD posttreatment in Wistar Kyoto rats and RD pretreatment in SHRSPs with AIS. Results-RD significantly ameliorated neurological deficit and infarct volume at 1 and 7 days after middle cerebral artery occlusion. RD immediately and continuously normalized elevated BP during 24 hours. This normalization of BP by RD was associated with the reduction of cerebral blood flow during both middle cerebral artery occlusion and reperfusion periods. Thus, RD-induced BP normalization seems to ameliorate cerebrovascular overperfusion in SHRSPs with AIS. On the contrary, RD did not affect cerebral vascular resistance or cerebral vasoreactivity and did not increase Akt and endothelial NO synthase phosphorylation, thereby indicating no apparent change of cerebrovascular function. RD significantly attenuated cerebral oxidative stress as estimated by dihydroethidium staining and gp91 phox expression. The beneficial effects were not seen in Wistar Kyoto rats, whereas RD pretreatment improved neurological function in SHRSPs. 
Conclusions-RD

Results
BP, Neurological Score, Cerebral Blood Flow, and Infarct Volume
Two SHRSPs in each MCAO group died during the study. Figure 1A and Figure IIA in the online-only Data Supplement show the continuous mean BP and averaged mean BP, respectively, of each group of SHRSPs over the period of pre-stroke, MCAO, and reperfusion (n=5). There was no significant difference between groups in baseline BP levels pre-stroke. In the sham-operated group, BP increased from 179±15 mm Hg prestroke to 215±7 mm Hg during MCAO and remained elevated during reperfusion (average BP of 210±2 mm Hg during 7-24 hours). Compared with the sham group, RD posttreatment immediately and continuously normalized BP between 135 and 156 mm Hg in the SHRSPs with MCAO group through 24 hours. There was no significant difference between the groups regarding the change in heart rate during the experiment (data not shown).
Although SHRSPs subjected to MCAO displayed significant neurological deficit, RD posttreatment significantly ameliorated neurological deficit at 1 day (n=6 in control and n=23 in MCAO groups; Figure 1B ) and 3 days (n=8) after MCAO.
In the sham group, ipsilateral cerebral blood flow (CBF) significantly decreased during MCAO and rapidly returned to control levels after reperfusion and subsequently decreased again (n=8-11; Figure 1C ). On the contrary, CBF in the RD group was significantly less than that in sham group at both 5 minutes before and after reperfusion. Contralateral CBF in the RD group was also less than that in the sham group and control group during the reperfusion state ( Figure IIB in the online-only Data Supplement).
Cerebral infarct volume in the RD group was smaller than that in the sham group at 1 day (n=8) and 7 days (n=8) after MCAO, and this difference was attributed to less infarct volume in the cortex of the RD group than in that of the sham group ( Figure 1D ; Figure IIC in the online-only Data Supplement). There was no apparent infarct lesion in the brain of the control group (SHRSPs without MCAO).
Cerebral Vascular Resistance and Cerebral Vasoreactivity
There was no significant difference in ipsilateral or contralateral cerebral vascular resistance (n=5; Figure 2A and 2B) and cerebral vasoreactivity to acetazolamide between the 
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sham and RD groups during MCAO and reperfusion (n=5; Figure 2C and 2D).
Akt, Endothelial NO Synthase, and Oxidative Stress
Cerebral phosphorylated Akt and phosphorylated endothelial NO synthase in SHRSPs were upregulated by MCAO, and the increase in these molecules was reversed by RD treatment (n=6, Figure IIIA and IIIB in the online-only Data Supplement). Cerebral superoxide levels in SHRSPs with MCAO were significantly reduced by RD posttreatment, which was associated with the significant reduction of gp91 phox by RD posttreatment (n=6; Figure IIIC and IIID in the online-only Data Supplement).
RD Posttreatment in Normotensive Ischemic Rats and RD Pretreatment in Hypertensive Rats
RD posttreatment did not show beneficial effects in normotensive ischemic Wistar Kyoto rats (n=8, Figure 3A and 3B).
Although RD pretreatment failed to reduce infarct volume, it improved neurological function in ischemic SHRSPs (n=8; Figure 3C and 3D).
Discussion
The major findings of this work were that RD posttreatment in the acute phase of ischemic stroke improved the outcome in hypertensive rats, as evidenced by the amelioration of neurological deficit and cerebral infarction. Although the effect of the RD pretreatment was relatively weak, our present work highlighted RD as a novel therapeutic strategy for AIS.
It is well known that chronic hypertension causes cerebral vascular remodeling and dysfunction, leading to the loss of the CBF autoregulation system. 4, 8 Furthermore, and importantly, CBF autoregulation is also lost in the ischemic brain region. It is true in SHRSPs, in which the loss of CBF autoregulatory function already occurs at the age of prestroke. 9 Under the lost CBF autoregulation system, further enhancement of high BP in AIS can promote cerebrovascular overperfusion and thereby exacerbate ischemic injury by aggravating cerebral edema. 4, 8 On the contrary, large decrease in BP to too low levels in AIS causes cerebrovascular hypoperfusion that subsequently progresses to ischemia in the salvageable penumbra. Thus, antihypertensive therapy in AIS is a double-edged sword. A modest degree of BP lowering may be potentially beneficial for the outcome of AIS. 3 Of note, in the present study, RD rapidly and continuously reversed the enhancement of high BP in SHRSPs subjected to MCAO. This reversal of BP elevation by RD was associated with the significant reduction of CBF around the reperfusion period. We also examined the impact of RD on oxidative stress in AIS, as oxidative stress plays a pivotal role in cerebral ischemia/reperfusion injury and the pathogenesis of stroke. 7, 10 In this study, we found that cerebral superoxide levels were significantly reduced by RD posttreatment, being associated with the decrease in cerebral gp91 phox , a major subunit of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Collectively, these findings support the notion that RD-induced normalization of elevated BP in SHRSPs with MCAO contributed to the improvement of outcome in AIS, by ameliorating high BP-induced cerebrovascular overperfusion and potentially attenuating brain oxidative stress. However, it cannot be excluded that the attenuation of oxidative stress might be secondary to the neuroprotection by RD. On the contrary, RD did not significantly affect cerebral vascular resistance or cerebral vasoreactivity and did not enhance the Akt/endothelial NO synthase pathway (a major pathway involved in vascular endothelial function). Therefore, RD might exert no apparent direct effect on cerebrovascular function in the AIS model.
Taken together, as the protective effects of RD were not observed in normotensive rats, we suggest that BP normalization in hypertensive ischemic stroke might ameliorate reperfusion injury by way of CBF reduction and improve the outcome. However, we did not assess the detailed mechanisms regarding the effectiveness of RD in this study; further studies will be needed to clarify the significances, including vascular protection of RD and the differences between pretreatment and posttreatment of RD against AIS. In addition, there was the limitation of CBF measurement under laser speckle flowmetry because the baseline might not be the same between the repeated experiments.
In conclusion, we obtained the first preclinical evidence that RD in the acute phase of ischemic stroke improved outcome in a hypertensive AIS model, and the effect was associated with appropriate BP normalization. However, further study is required to determine the significance of hypertension during AIS. 
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